BIO Mar 2023 410.000 call
| Previous close | 64.18 |
| Open | 64.22 |
| Bid | 63.10 |
| Ask | 71.20 |
| Strike | 410.00 |
| Expiry date | 2023-03-17 |
| Day's range | 61.75 - 64.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
- GlobeNewswire
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis SystemsFREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered into a strategic partnership with leading life science research and clinical diagnostics products company Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). Under the terms of the agreement, Bio-Rad’s exceptionally bright, high-perf
- Zacks
VAREX IMAGING (VREX) Misses Q1 Earnings Estimates
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -27.27% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.
